|
Amgen, AstraZeneca prep a brodalumab pitch–after scuttling asthma program
FierceBiotech Amgen and its partner AstraZeneca are winding up to deliver U.S. and European applications for their big blockbuster hopeful brodalumab for plaque psoriasis by mid-year. But their last shot to push ahead with the drug in asthma ran into defeat, with … |
View full post on asthma – Google News